Ground breaking molecular diagnostics business appoints new Head of Marketing

現在、このページはご希望の言語でご利用いただけません。 Google 翻訳を使用すると自動翻訳でページを表示できます。 弊社はこのサービスの提供に責任を持たず、翻訳結果を弊社でチェックすることはありません。
さらにサポートをご希望の場合は、弊社までお問い合わせください。

Jim Greaves is appointed Head of Marketing for Renishaw Diagnostics Ltd

ページコンテンツダウンロード各国事務所へのお問い合わせ オンラインでのお問い合わせ

Glasgow, Scotland, 17 August 2010

Jim Greaves, Renishaw Diagnostics LtdRenishaw Diagnostics Ltd, a world leading provider of trace level detection technologies based on the exploitation of Surface Enhanced Raman Spectroscopy (SERS) and Surface Enhanced Resonance Raman Scattering (SERRS), today announced that it has appointed Jim Greaves as Head of Marketing. He will help prepare the organisation for the international launch of its first in-vitro diagnostic (IVD) products, with the aim to establish Renishaw Diagnostics as a global player in the field of molecular diagnostics for human infectious diseases. Dr Greaves has over 25 years of commercial life sciences experience, including Director of Marketing at Invitrogen, Business Development Director at CXR Biosciences and Director of Marketing at ITI Life Sciences.

The Company’s CEO, David Burns, said, “I am delighted to welcome Jim to the Company. We already have a strong multi-disciplinary technical team and his proven marketing skills and commercial experience will be important to the successful launch of our exciting portfolio of research and molecular diagnostics products that Renishaw Diagnostics has planned for the next few years.”

Dr Greaves, who holds a PhD in bacterial genetics, has gained extensive knowledge of sales, marketing and business development within scientific and technical sectors. Prior to Invitrogen, he also held senior roles within Mettler Toledo, Shandon Scientific, Fisher Scientific and Sarstedt, and also worked in the Public Health Laboratory Service. “I am very excited by this new challenge,” said Dr Greaves. “Renishaw Diagnostics has a tremendous future with our multiplex diagnostic platform and I am excited at helping the team deliver world-class DNA-based diagnostic tests to detect diseases, or the genetic predisposition to diseases.”

About Renishaw Diagnostics Ltd
Renishaw Diagnostics Ltd, formerly D3 Technologies Ltd, was a Strathclyde University spin-out before being acquired by the Renishaw Group, which is a leading global supplier of engineering technologies, medical devices and Raman spectroscopy systems. It is focused on developing and commercialising its first in vitro diagnostic (IVD) and clinical research products, with the goal of establishing Renishaw Diagnostics as the premium provider of automated, multiplex, high sensitivity molecular diagnostics products for the detection of human infectious diseases. The Company is based in Glasgow, Scotland, and further information is available at www.renishawdiagnostics.com.  

All images and text copyright Renishaw

Register for news updates

Register for regular news updates from Renishaw

お問い合わせ

詳細価格についてのお問い合わせは、オンラインでお寄せ下さい。直接コンタクトをご希望の場合は、 現地レニショーオフィスまでご連絡ください。